Tag: M.W:100-200

1126-58-5, 1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a magnetically stirred solution of substituted isatin (5mmol) in 7ml of absolute ethanol, a corresponding pyridinium acetohydrazide (5mmol) and three drops of trifluoroacetic acid were successively added. The reaction mixture was heated under reflux for 3h. After spontaneously cooling the solution to room temperature, the precipitate formed was filtered, washed with absolute ether and dried in vacuo., 1126-58-5

As the paragraph descriping shows that 1126-58-5 is playing an increasingly important role.

Reference£º
Article; Bogdanov, Andrei V.; Zaripova, Ilyuza F.; Voloshina, Alexandra D.; Sapunova, Anastasia S.; Kulik, Natalia V.; Tsivunina, Irina V.; Dobrynin, Alexey B.; Mironov, Vladimir F.; Journal of Fluorine Chemistry; vol. 227; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5,4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1,4,7-Triazacyclononane (41 mg, 0.32 mmol, 1 equiv.) and6-(bromomethyl)-2-methyl-3-nitropyridine. (258 mg, 1.12 mmol, 3.5 equiv.) were dissolved in 8 mL of dry acetonitrile followed by addition of triethylamine (180 .iL, 1.29 mmol, 4 equiv.). The reaction mixture was stirred at 50 C for 24 hours under argon. Upon completion of the reaction, solvent was removed in vacuo producing a brown oily residue. The crudeproduct was purified by reversed-phase HPLC using a gradient of solvent B from 30% to70% in solvent A over 40 minutes. ESI-MS analyses of fractions with retention time tR = 21minute confirmed product iv. These fractions were combined and solvent was removed bylyophilization producing iv in the form of TFA salt. Yield: 80 mg, 63 .imol, 20%. ?H NMR,500 MHz (CD3OD, ppm): oe = 8.35 d (3H, Ar, J = 9 Hz), 7.55 d (3H, Ar, J = 9 Hz), 4.32 s(6H, 3CH2), 3.23 m (12H, 6CH2), 2.78 s (9H, 3CH3). ?3C NMR, 75 MHz (CD3OD, ppm): oe =160.60, 154.51, 146.59, 134.91, 123.40, 60.07, 50.74, 23.92. High-resolution ESI-MS (mlz):[M+H], calculated: 580.2627, found: 580.2691.

As the paragraph descriping shows that 4730-54-5 is playing an increasingly important role.

Reference£º
Patent; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK UNIVERSITY AT BUFFALO; HEALTH RESEARCH, INC.; MORROW, Janet, R.; TSITOVICH, Pavel, B.; DORAZIO, Sarina, J.; OLATUNDE, Abiola, O.; SNYDER, Eric, M.; SPERNYAK, Joseph, A.; BURNS, Patrick; BOND, Christopher, J.; WO2015/38943; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13040-77-2,6-Chloro-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

The reaction was performed under argon. Substituted azole (excess) and potassium tert-butoxide were dissolved at RT in dry and degassed DMSO. An exothermic reaction occurred. The mixture was stirred for 10 min to allow the reaction to finish and cool. Then, a substituted halopyridine was added. The reaction mixture was stirred for 24 h at 140C to give a suspension. It was cooled to RT. Water (50mL) was added: the product precipitated on stirring/sonication. The solid was filtered, washed with water, and extracted with dichloromethane and water. The organic layer was washed with water to extract DMSO. Purification by chromatography on silica (20g) removed the starting materials and by-products on elution with 0-0.4% CH3OH in CH2Cl2, and provided the pure product on elution with 0.4-1.0% CH3OH in CH2Cl2. Anal. Calc. for C15H14N4 (MW 250.30): C, 71.98; H, 5.64; N, 22.38. Found: C, 72.04; H, 5.48; N, 22.48%.

13040-77-2, 13040-77-2 6-Chloro-2,2′-bipyridine 11116850, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Shavaleev, Nail M.; Kessler, Florian; Graetzel, Michael; Nazeeruddin, Mohammad K.; Inorganica Chimica Acta; vol. 407; (2013); p. 261 – 268;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

NOTPA was prepared by the reaction of 1,4,7-triazacyclonoanane (TACN) (1 mmol, 0.10 g) and acrylic acid (3 mmol, 0.16 g) in acetone (30 mL), the reaction mixture was stirred at room temperature for 2 h to give a yellowish precipitate. The resulting precipitate was filtered and washed with diethyl ether and ethanol and dried in a vacuum oven to give a light yellow powder in 80 % yield (0.27 g). FTIR (KBr, Vmax, cm-1): 3411, 3231, 2935, 2845, 2350, 1751, 1654, 1402, 1240, 621; 1H NMR (400 MHz, DMSO, delta): 12.02 (s. 3H, OH). 3.62 (s, 6H, -CH2-CH2-C=0), 3.02 (s, 6H, N-CH2-CH2-C=O), 2.36 (t, 12H, N-CH2-CH2-N): 13C NMR (100 MHz, DMSO, delta) 172.80, 60.83, 52.12, 35.65 ppm; Anal. C15H27N306 (345.0): Calc: C, 52.17; H, 7.82; N, 12.17; found: C, 52.08; H, 7.70; N, 12.04% .

4730-54-5 1,4,7-Triazacyclononane 188318, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Alshehri, Saad M.; Al-Farraj, Eida; Alhokbany, Norah; Ahamad, Tansir; Asian Journal of Chemistry; vol. 27; 6; (2015); p. 2209 – 2216;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.

A solution of N(4-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide(0.100 g, 0.255 mmol), D-(-)-prolinamide (0.058 g, 0.5 11 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stilTed at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, Cl 8; acetonitrile / aqueous 0.1%-formic acid solution = 10 % to 90 %) to give (R)- 1 -(2-(N-(4-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)e thyl)pyffolidine-2-carboxamide as white solid (0.120 g, 92.9 %).?H NMR (400 MHz, DMSO-d6) oe 7.96( d, 2 H,J = 8.4 Hz), 7.50 (d, 2 H, J = 8.3 Hz), 7.43 -7.22 (m, 6 H), 7.11 (br, 2 H), 5.00 (s, 2 H), 4.02 (q, 1 H, J= 5.2 Hz), 3.47 (m, 2 H), 3.32 (s, 1 H), 3.15 – 3.13 (m, 1 H), 2.94 – 2.81 (m, 2 H), 2.34 – 2.30 (m, 1 H), 2.06 (m, 1 H), 1.74 – 1.69 (m, 2 H); LRMS (ES) mlz 506.1 (M+1).

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; CHONG KUN DANG PHARMACEUTICAL CORP.; LEE, Jaekwang; HAN, Younghue; KIM, Yuntae; CHOI, Daekyu; MIN, Jaeki; BAE, Miseon; YANG, Hyunmo; KIM, Dohoon; (644 pag.)WO2017/18803; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

162318-34-5, 5-Ethynyl-2,2′-bipyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

For the cross-coupling reaction leading to 5-ethynyl-2,2?-bipyridine (0.150 g, 0.83 mmol), the 5-bromo-2,2?-bipyridine (0.200 g, 0.83 mmol) was dissolved in benzene at 80 C. When a clear solution was obtained, [Pd(PPh3)4] (0.092 g, 0.08 mmol) and 5 mL of triethylamine were added. After 24 h of heating at 80 C, the solvent was removed under vacuum and the residue was purified by flash column chromatography (silica gel, MeOH/CH2Cl2 = 1/9). Yield: 48% (133 mg), TLC (SiO2): Rf 0.28 (10% methanol/dichloromethane); IR (KBr, cm-1) 3053 (Ar-H), 3008 (Ar-H), 2923 (Ar-H), 2850 (Ar-H), 1456 (aromatic C=C), 798 (Ar-C), 1H NMR (400 MHz, CDCl3) delta 7.32-7.35 (m, 2H, PyH), 7.82-7.86 (m, 2H, PyH), 7.97-8.00 (m, 2H, PyH), 8.43-8.46 (m, 4H, PyH), 8.70-8.71 (m, 2H, PyH), 8.85-8.86 (m, 2H, PyH); HRMS: m/z calc. for C22H14N4: calc. for 336.1375, found 336.1369., 162318-34-5

The synthetic route of 162318-34-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Kim, Minki; Kang, Chang Hoon; Hong, Subong; Lee, Won-Yong; Kim, Byeong Hyo; Inorganica Chimica Acta; vol. 395; (2013); p. 145 – 150;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5

General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

294-90-6, 1,4,7,10-Tetraazacyclododecane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

N-(tert-Butoxycarbonyloxy)succinimide (2.50 g, 11.62 mmol) inchloroform (30 mL) was added dropwise into the solution of1,4,7,10-tetraazacyclododecane (1.00 g, 5.80 mmol) in CHCl3(50 mL) during 7 h. The reaction mixture was stirred 24 h at roomtemperature and the solvent was removed under reduced pressure. The residue was suspended in aqueous NaOH (3 M, 50 mL) and theaqueous phase was extracted with CHCl3 (3 50 mL). The combinedextracts were dried with K2CO3 and evaporated to drynessto give 1,7-bis(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane(10) in quantitative yield.1,3,5-Tris(bromomethyl)benzene (7.65 g, 21.62 mmol) was dissolvedin CHCl3 (150 mL) and Na2CO3 (1.71 g, 16.15 mmol) wasadded. Compound 10 (1.08 g, 2.90 mmol) in CHCl3 (50 mL) wasadded dropwise into the reaction mixture during 11 hours at52 C. The reaction mixture was refluxed for 3 days at 62 C,filtrated, and evaporated to dryness. The residue was purified bysilica gel chromatography (40-70% EtOAc in hexane), giving 11 in27% yield (0.722 g). 1H NMR (500 MHz, CDCl3) d 7.33 (s, 6H), 4.45(s, 8H), 3.71 (s, 4H), 3.21-3.57 (m, 8H), 2.55-2.68 (m, 8H), 1.27(s, 18H). 13C NMR (100 MHz, CDCl3) dppm 155.8, 140.8, 138.5,129.9, 128.3, 79.3, 59.5, 55.2, 46.1, 32.9, 28.4. HRMS(ESI): obsd.921.0840 [M+H]+, Calcd. 921.0795 [M+H]+., 294-90-6

The synthetic route of 294-90-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Laine, Maarit; Loennberg, Tuomas; Helkearo, Mia; Loennberg, Harri; Inorganica Chimica Acta; vol. 452; (2016); p. 111 – 117;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10581-12-1, Tetramethylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

CORM-349 [Me4N][(OC)3Mn(mu-OCOCH3)3Mn(CO)3]; 150 mg (0.436 mmol) of Mn(CO)5(SO3CF3) and 116 mg (0.872 mmol) of [Me4N][acetate] were stirred in 8 ml of dry THF and 2 ml of methanol, under argon at 50-55 C. for 3 hrs. During this time the colour of the solution went a little darker yellow/orange.Following this, the solvent was removed on rotary evaporator to give a yellow/orange semi-solid residue. This was crystallised from DCM/Ether at -18 C. to give a yellow crystalline product (123 mg, 0.232 mmol). Yield was 100%.Based on the preliminary IR data, the product was initially identified as [Me4N][(Mn(CO)4(OAc)2]. However, additional analysis, particularly X ray crystal structure analysis, has revealed that the product has the title structure. Furthermore, mass spectral data also supports a product having more than one Mn atom.Mr=529.21.1H NMR (CD2Cl2): delta(ppm) 2.29 (s, acetate CH3 6H), 3.33 (s, NMe4 12H)13C NMR (CD2Cl2): delta(ppm) 23.55 (acetate CH3), 56.34 (NMe4), 176.15 (CO), 224.20 (CO)17O NMR (CD2Cl2): delta(ppm) 388.6 (CO)IR (CH2Cl2) nu(cm-1): 2027 (s), 1930 (vs)Mass Spec (ES-) (m/z): 455 ([Mn2(CO)6(OAc)3]-); 315 ([Mn2(CO)(OAc)3]- or [Mn2(CO)4(OAc)(OH)2]-); 257 ([Mn(CO)3(OAc)2]-)Elemental: C16H21Mn2NO12 found (calc) C: 36.80 (36.31), H: 4.90 (4.00), N: 3.60 (2.65)The dimeric structure of the anion has been established by x-ray crystallography.

10581-12-1, As the paragraph descriping shows that 10581-12-1 is playing an increasingly important role.

Reference£º
Patent; Motterlini, Roberto Angelo; Mann, Brian Ernest; Scapens, David Alistair; US2010/105770; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5

A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI